Muscle loss in men with prostate cancer on hormone therapy
SArcopenia in Men with Prostate Cancer undergoing ADT (SAP-ADT)
This project will follow men starting androgen deprivation (hormone) therapy for prostate cancer to track muscle loss, strength, and quality of life over 12 months.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Inst for Biomedical/clinical Res NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11258962 on NIH RePORTER |
What this research studies
If you join, you'll be one of about 70 men who start ADT and will be followed with regular visits for a year. Researchers will measure body composition with scans, test muscle strength and walking ability, collect blood samples and optional muscle biopsies, and ask about symptoms and daily function. They will study biological pathways including mitochondrial changes and search for clinical measurements that predict who loses muscle. The team will also collect patient-reported quality-of-life information to better understand the lived experience of muscle loss during treatment.
Who could benefit from this research
Good fit: Ideal candidates are men with a diagnosis of prostate cancer who are about to start or have recently started androgen deprivation therapy and can attend study visits for 12 months.
Not a fit: Men not receiving ADT, those with severe medical issues that prevent study procedures (such as muscle biopsy), or those unwilling to complete follow-up are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this work could help doctors predict who will lose muscle on ADT and guide future treatments to preserve strength and quality of life.
How similar studies have performed: Previous research has shown ADT commonly causes muscle loss but there are no approved drugs for sarcopenia and predicting who will develop it is still largely untested, so elements of this work are novel.
Where this research is happening
Seattle, United States
- Seattle Inst for Biomedical/clinical Res — Seattle, United States (Active)
Researchers
- Principal investigator: Garcia, Jose M. — Seattle Inst for Biomedical/clinical Res
- Study coordinator: Garcia, Jose M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.